Back to Search
Start Over
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALKVariant Type and ALKWith or Without TP53Mutations
- Source :
- Journal of Thoracic Oncology; November 2023, Vol. 18 Issue: 11 p1581-1593, 13p
- Publication Year :
- 2023
-
Abstract
- Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes compared with crizotinib in patients with previously untreated ALK-positive advanced NSCLC in the phase 3 CROWN study. Here, we investigated response correlates using plasma circulating tumor DNA (ctDNA) and tumor tissue profiling.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Volume :
- 18
- Issue :
- 11
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs63689423
- Full Text :
- https://doi.org/10.1016/j.jtho.2023.07.023